{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:26:07Z","timestamp":1792153567775,"version":"4.4.0"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T00:00:00Z","timestamp":1541116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0206865","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T14:15:51Z","timestamp":1541168151000},"page":"e0206865","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":62,"title":["Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-8735","authenticated-orcid":true,"given":"Yukihiro","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taihei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-5327","authenticated-orcid":true,"given":"Shohei","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Iseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonori","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Iyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"A McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40620-016-0360-z","article-title":"Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients","volume":"30","author":"R Coppo","year":"2017","journal-title":"J Nephrol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1681\/ASN.2012010063","article-title":"Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria","volume":"23","author":"E Gutierrez","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10157-011-0552-8","article-title":"A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission?","volume":"16","author":"H Imai","year":"2012","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10157-013-0921-6","article-title":"Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy","volume":"18","author":"Y Suzuki","year":"2014","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"DC Cattran","year":"2009","journal-title":"Kidney Int"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"IS Roberts","year":"2009","journal-title":"Kidney Int"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00467-016-3469-3","article-title":"Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort","volume":"32","author":"R Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/joneph\/18.5.503","article-title":"Factors predicting progression of IgA nephropathies","volume":"18","author":"R Coppo","year":"2005","journal-title":"J Nephrol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5301\/jn.5000151","article-title":"A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease","volume":"26","author":"T Kawamura","year":"2013","journal-title":"J Nephrol"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2215\/CJN.03270410","article-title":"Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability","volume":"5","author":"MC Hastings","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"e0166830","DOI":"10.1371\/journal.pone.0166830","article-title":"Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy","volume":"11","author":"MJ Kim","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"e1006609","DOI":"10.1371\/journal.pgen.1006609","article-title":"GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway","volume":"13","author":"K Kiryluk","year":"2017","journal-title":"PLoS Genet"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Z Moldoveanu","year":"2007","journal-title":"Kidney Int"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"e0188718","DOI":"10.1371\/journal.pone.0188718","article-title":"Biomarkers of IgA vasculitis nephritis in children","volume":"12","author":"E Pillebout","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"e0190967","DOI":"10.1371\/journal.pone.0190967","article-title":"Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy","volume":"13","author":"WJ Placzek","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"e0166700","DOI":"10.1371\/journal.pone.0166700","article-title":"Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review","volume":"11","author":"Q Sun","year":"2016","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"7806438","DOI":"10.1155\/2016\/7806438","article-title":"Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?","volume":"2016","author":"H Suzuki","year":"2016","journal-title":"Dis Markers"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"H Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"ref20","first-page":"629","article-title":"IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1","volume":"118","author":"H Suzuki","year":"2008","journal-title":"J Clin Invest"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","article-title":"IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis","volume":"93","author":"H Suzuki","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"e98081","DOI":"10.1371\/journal.pone.0098081","article-title":"A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases","volume":"9","author":"H Yanagawa","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/ki.2012.197","article-title":"The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression","volume":"82","author":"N Zhao","year":"2012","journal-title":"Kidney Int"},{"issue":"6","key":"ref24","first-page":"1668","article-title":"Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity","volume":"119","author":"H Suzuki","year":"2009","journal-title":"J Clin Invest"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI74475","article-title":"The genetics and immunobiology of IgA nephropathy","volume":"124","author":"K Kiryluk","year":"2014","journal-title":"J Clin Invest"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.krcp.2016.09.001","article-title":"Diagnosis and treatment of patients with IgA nephropathy in Japan","volume":"35","author":"Y Tomino","year":"2016","journal-title":"Kidney Res Clin Pract"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfv221","article-title":"Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy","volume":"30","author":"J Yasutake","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"ref28","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"J Coresh","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ccd.20217","article-title":"Validation of a new formula for mean arterial pressure calculation: the new formula is superior to the standard formula","volume":"63","author":"M Razminia","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10157-012-0660-0","article-title":"Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy","volume":"17","author":"Y Wada","year":"2013","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.ajkd.2007.09.004","article-title":"Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan","volume":"50","author":"E Imai","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1007\/s10157-017-1408-7","article-title":"Effect of tonsillectomy with steroid pulse therapy on circulating tumor necrosis factor receptors 1 and 2 in IgA nephropathy","volume":"21","author":"M Murakoshi","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"ref33","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"T Kawamura","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"ref34","first-page":"123","article-title":"Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version","volume":"53","author":"S Matsuo","year":"2011","journal-title":"Jpn J Nephrol"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"e0158154","DOI":"10.1371\/journal.pone.0158154","article-title":"Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy","volume":"11","author":"K Hihara","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1681\/ASN.2010111158","article-title":"Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease","volume":"22","author":"M Iyoda","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"e111728","DOI":"10.1371\/journal.pone.0111728","article-title":"Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats","volume":"9","author":"Y Wada","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"ref38","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ndt\/gfm913","article-title":"Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy","volume":"23","author":"S Shimozato","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"8210641","DOI":"10.1155\/2017\/8210641","article-title":"Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls","volume":"2017","author":"JT Sanders","year":"2017","journal-title":"Int J Nephrol"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","article-title":"New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schonlein purpura)","volume":"16","author":"MH Heineke","year":"2017","journal-title":"Autoimmun Rev"},{"key":"ref41","article-title":"Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort","author":"L Berthelot","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1074\/jbc.M113.512277","article-title":"Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes","volume":"289","author":"H Suzuki","year":"2014","journal-title":"J Biol Chem"},{"issue":"5","key":"ref43","first-page":"7861","article-title":"Serum galactose-deficient IgA1 levels in children with IgA nephropathy","volume":"8","author":"M Jiang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"e89707","DOI":"10.1371\/journal.pone.0089707","article-title":"Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy","volume":"9","author":"J Nakata","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"ref45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ki.2015.158","article-title":"Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes","volume":"88","author":"L Berthelot","year":"2015","journal-title":"Kidney Int"},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/315467","article-title":"Serum galactose-deficient IgA1 level is not associated with proteinuria in children with IgA nephropathy","volume":"2012","author":"MC Hastings","year":"2012","journal-title":"Int J Nephrol"},{"issue":"8","key":"ref47","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2215\/CJN.11571210","article-title":"Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy","volume":"6","author":"R Camilla","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"ref48","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in Japan","volume":"63","author":"K Suzuki","year":"2003","journal-title":"Kidney Int"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"F Berthoux","year":"2012","journal-title":"J Am Soc Nephrol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0206865","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:15:36Z","timestamp":1775258136000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0206865"}},"subtitle":[],"editor":[{"given":"Ivan Cruz","family":"Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0206865","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]}}}